Novavax Shows 96.4% Efficiency Against Baseline COVID-19

MOSCOW, 12 Mar – RIA Novosti. The Novavax coronavirus vaccine was 96.4% effective against the original coronavirus and 86.3% against the British strain, the American biotech company said in a statement.

The third phase of the NVX CoV2373 vaccine trial took place in the UK. The study covered more than 15 thousand participants aged 18 to 84 years old, 27% of them were over 65 years old.

The company also said that when it comes to severe disease, the drug has demonstrated 100% effectiveness.

Author: wedocount

Leave a Reply

Your email address will not be published. Required fields are marked *